Holen Sie sich die Stockscreener-App
33.28
6.97%
2.2641
Schlusskurs vom Vortag:
$31.02
Offen:
$29.99
24-Stunden-Volumen:
518.35K
Relative Volume:
0.70
Marktkapitalisierung:
$1.90B
Einnahmen:
$205.63M
Nettoeinkommen (Verlust:
$40.57M
KGV:
50.44
EPS:
0.6599
Netto-Cashflow:
$52.37M
1W Leistung:
-9.04%
1M Leistung:
-3.46%
6M Leistung:
+44.90%
1J Leistung:
+301.71%
1-Tages-Spanne:
$29.86
$33.42
1-Wochen-Bereich:
$29.86
$37.49
52-Wochen-Spanne:
$5.35
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
33.27 | 1.77B | 205.63M | 40.57M | 52.37M | 0.6599 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.46 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
739.12 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
683.88 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.59 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.94 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-05 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics earnings missed by $0.21, revenue fell short of estimates - Investing.com Canada
Stoke Therapeutics (NASDAQ: STOK) launches $150M ATM sales agreement with Cantor - Stock Titan
Stoke Therapeutics (STOK): Analyst Ratings and Price Target Upda - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Chardan Capital - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Stoke Therapeutics (STOK), NRX Pharmaceuticals (NRXP) and Airsculpt Technologies (AIRS) - The Globe and Mail
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 17, 2026 - BioSpace
Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop? - Kalkine Media
Stoke Therapeutics (STOK) Quarterly Losses Test Newly Profitable Trailing Earnings Narrative - simplywall.st
STOK: Wedbush Raises Price Target for Stoke Therapeutics | STOK Stock News - GuruFocus
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 605 Shares of Stock - MarketBeat
Stoke Therapeutics (STOK) chief patient officer exercises 10,000 RSUs into shares - Stock Titan
Stoke Therapeutics (STOK) CFO exercises 14,750 RSUs, now holding 14,750 shares - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) CMO exercises 33,850 RSUs - Stock Titan
Stoke Therapeutics (STOK) director adds 61,750 shares through RSU settlements - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) counsel exercises 25,475 RSUs into shares - Stock Titan
Director at Stoke Therapeutics (STOK) sells 605 shares in plan trade - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down on Disappointing Earnings - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Needham Raises Price Target for Stoke Therapeutics (STOK) to $40 | STOK Stock News - GuruFocus
Stoke Therapeutics 2025 10-K: Advancing RNA-Based Medicines with TANGO Platform for Genetic Diseases - Minichart
Decoding Stoke Therapeutics Inc (STOK): A Strategic SWOT Insight - GuruFocus
Why Stoke Therapeutics (STOK) Is Down 11.4% After NEJM Data on Dravet Syndrome DrugAnd What's Next - simplywall.st
Stoke Therapeutics (NASDAQ:STOK) Issues Earnings Results, Misses Expectations By $0.22 EPS - MarketBeat
Stoke Therapeutics (NASDAQ: STOK) outlines Dravet Phase 3 plan and $165M Biogen alliance - Stock Titan
Stoke Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Stoke Therapeutics Hits Day Low at $33 Amid Price Pressure - Markets Mojo
Granahan Investment Management LLC Sells 278,514 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Checkpoint Capital L.P. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc.Common Stock (NQ: STOK - The Chronicle-Journal
[144] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Stoke Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 6.6% Following Insider Selling - MarketBeat
Aug Weekly: Can Stoke Therapeutics Inc grow without external fundingMarket Growth Review & Stock Market Timing Techniques - baoquankhu1.vn
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 33,243 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $174,200.00 in Stock - MarketBeat
Insider Sell: Adrian Krainer Sells 33,243 Shares of Stoke Therap - GuruFocus
Stoke Therapeutics Director Sells Over 33,000 Shares - TradingView
Stoke Therapeutics (STOK) chair exercises options, sells 4,355 shares under 10b5-1 plan - Stock Titan
Director at Stoke Therapeutics (STOK) sells 33K shares under 10b5-1 plan - Stock Titan
Stoke Earnings: Clinical Narrative Eclipses Financial Disclosure - Trefis
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Highs Report: Is Stoke Therapeutics Inc in a long term uptrendPortfolio Risk Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Cresset Asset Management LLC Invests $771,000 in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD By Investing.com - Investing.com Canada
Morgan Stanley Smith Barney files Rule 144 notice listing 58,769 and 31,739 STOK shares (STOK) - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Hits New 52-Week HighStill a Buy? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD - Investing.com
Stoke Therapeutics earnings in focus amid Dravet trial progress - Investing.com South Africa
Stoke Therapeutics earnings in focus amid Dravet trial progress By Investing.com - Investing.com India
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):